Core purchase flow works, but one payment retry defect should be resolved before the release is promoted to all users.
DEMONSTRATION DELIVERABLE
Sample QA Release Readiness Report
This is a fictional example created only to show the structure and level of detail a client handover can contain. It is not a real client report and contains no client data.
EXECUTIVE SUMMARY
Release recommendation: Conditional
Retrying a failed payment can create a duplicate order record in one edge case.
Resolve the high-risk finding, rerun checkout regression and verify API idempotency.
SCOPE
What was checked
Guest checkout, registered checkout, account creation and order confirmation.
Payment request, retry handling, error responses and order status update.
Existing discount code, tax calculation, cart persistence and confirmation email.
Current Chrome and Edge desktop plus a compact mobile viewport smoke check.
FINDINGS
Prioritized issues
| ID | Severity | Area | Finding | Recommended action |
|---|---|---|---|---|
| QA-01 | High | Payments | Retry after timeout can create a duplicate order record. | Add idempotency protection and rerun retry-path regression. |
| QA-02 | Medium | Checkout UI | Error message disappears after navigating back to payment step. | Persist the validation state until the user changes payment data. |
| QA-03 | Medium | API | One validation error returns a generic 500 instead of a 4xx response. | Return a client-safe validation response and add an API regression check. |
| QA-04 | Low | Mobile | Order summary wraps awkwardly at a narrow viewport. | Adjust responsive spacing before the next UI polish pass. |
EVIDENCE & HANDOVER
What the client receives
Short, repeatable steps for each actionable finding.
Screenshots, request/response samples or logs where they add value.
What is known, what remains uncertain and what should be retested.
A prioritized list that makes the handover useful to developers and product owners.
RELEASE DECISION
Proceed after QA-01 is fixed and the payment retry path passes regression.
Remaining medium and low findings can be accepted only if the product owner explicitly agrees to the documented risk.